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Abstract  
 
Context: A large number of minimally invasive techniques (MITs) have been developed for 
the surgical management of male lower urinary tract symptoms presumed secondary to 
benign prostatic obstruction (LUTS/BPO) over the last three decades. Many have not stood 
the test of time often because they were over promoted before there were sufficient data. 
Objectives: The scope of this paper is to consider whether new devices, for the treatment of 
male LUTS/BPO, have been implemented prematurely in the past. We also examine the 
relative certainty of evidence (CoE) that is currently available for the newer developing 
technologies and make recommendations about the CoE that should be demanded in the 
future before widespread implementation.   
Key Messages: This evidence must provide adequate lengths of follow up to allow proper 
information to be provided for patients before treatment choices are made and to be able to 
create recommendations in high quality guidelines such as those of the European Association 
of Urology (EAU). It’s not just within the domain of LUTS treatments that this is important; 
other urological devices, such as mesh devices, have been equally ‘guilty’ and likewise 
devices in most other (surgical) specialties. 
We believe that there is a need for a set of requirements built around primary randomised 
controlled trials (RCTs) looking at both efficacy and safety and secondary studies to confirm 
the reproducibility and the generalisability of the first pivotal studies. Otherwise there is a 
danger that a single pivotal study can be over exploited by the device manufacturers. 
Studies that are needed include i) proof of concept, ii) RCTs on efficacy and safety as well as 
iii) cohort studies with a broad range of inclusion and exclusion criteria to confirm both 
reproducibility and generalisability of the benefits and harms. 
 
 3 
It is not the purpose of this paper to make judgements about individual treatments but simply 
to look at different treatments to provide verification for this debate. 
 
Patient Summary 
 
Many new device treatments have been developed over the last 20-30 years, often with 
inadequate medium to long-term results. Many have not stood the test of time but were 
heavily promoted by the manufacturers, the press, and some doctors, when they were first 
released, meaning that many patients had unsatisfactory results. This paper proposes 
minimum standards for the investigation of new treatments before their widespread 
promotion to patients.  
 
Introduction 
 
It is a common perception that surgical rather than medical intervention becomes appropriate 
in those patients with bothersome LUTS due to benign prostatic obstruction (BPO), who are 
unwilling to try medical therapies, or in cases where medical therapies are ineffective or not 
well tolerated, and in cases of complicated LUTS.  However, with the advent of more 
minimally invasive treatments the threshold for surgical intervention has become much 
lower1.  
This paper is the opinion of the current EAU male LUTS guideline development group and 
has been developed after considerable review of the current literature on the novel treatment 
devices. 
A large number of MITs have been developed for the management of male LUTS/BPO, in 
the last three decades or so. From the middle of the 1980s onwards attempts to use balloon 
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dilation of the prostate, prostatic stents, prostate hyperthermia and cryotherapy, 
Neodymium:YAG based therapies of the prostate like interstitial laser coagulation (ILC) or 
visual laser ablation of the prostate (VLAP), transurethral needle ablation (TUNA), 
transurethral microwave therapy (TUMT) and high intensity focused ultrasound (HIFU) have 
all had strong advocates, but over time many devices have not stood the test of time and have 
fallen out of favour. These may have disappeared for a variety of reasons, such as lack of 
long-term efficacy, adverse events, poor cost effectiveness or the development of newer 
versions (the ‘industrial/commercial circle’), which again dilutes the data available on the 
latest or current version of the device.  
 
It is important to bear in mind, from the start, that patients’ and clinicians’ expectations of 
outcomes may differ. For instance, patients (compared to clinicians) may prefer treatment 
options that are less effective if they result in a smaller risk of complications or a faster return 
to normal activities. There is little doubt that there is a desire from patients for MITs. 
Unfortunately, sometimes the eagerness for these new MITs, both in the popular press – the 
commonest source of direct patient information – but sometimes also from the early adopters 
of the treatment, has meant that this enthusiasm has often outstripped the clinical evidence. 
Early and aggressive company marketing can also over-power clinical evidence. Unlike 
pharmaceutical interventions, implementation of novel devices and techniques into clinical 
practice is not governed by the same strict regulatory mechanisms2. 
Therefore, the quality of the studies must remain high: i) there must be adequate control arms 
(for instance, compared to sham treatment or to other established comparable therapies), ii) 
outcomes that are patient-important, including patient reported outcome measurements 
(PROMS), and iii) include a relevant study population that is generalisable.  
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We also need to remember that behind the tool itself, there is also a concept: ablation, 
resection, enucleation… therefore a new device for resection is not a new device for 
vaporisation. Some of the principles behind these ‘failed’ treatments have been born again 
using newer or more powerful devices. It is therefore important that unlike their predecessors, 
sufficient controlled trials are carried out before their widespread application.  Certain 
concepts however, such as (laser) enucleation have resulted in a paradigm change in the 
surgical management of LUTS/BPO.  
 
 
Long-term unsuccessful treatments 
 
In 1988, transurethral balloon dilatation of the prostate was reported as a safe and simple 
procedure which could be performed on an outpatient basis using topical anaesthesia and 
sedation with minimal morbidity3. Two years later however, another series claimed that 
significant improvement in objective measurement of outflow obstruction was noted in only 
two out of fourteen patients4  
Another example was TUNA where again early results promised significant improvements in 
both subjective and objective outcomes: “TUNA is a promising, anaesthesia-free alternative 
treatment for men with symptomatic BPH” 5. Yet a few years later a study reported that 
“TUNA produced an unsatisfactory clinical result” 6. The overall retreatment rate after 
TUNA™ was 19% based on an analysis of seventeen non-comparative studies (median 
follow-up unreported; only three out of seventeen studies had follow-up exceeding two years; 
a rate considerably higher than that seen with TURP 7. A very high re-intervention rate for 
BPO was also reported in another French study of TUNA8 
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Many of these and similar studies, in their conclusions, promised prospective randomised 
studies to determine the role of treatment ‘x’ in the management of LUTS, but these rarely 
materialised. 
How to assess Certainty of Evidence 
 
The CoE in urological clinical research literature is generally very low, and the reporting is 
inadequate9. The Idea, Development, Exploration, Assessment, Long-term (IDEAL) study 
recommendations have been established as a potential solution by serving as guidelines 
tailored to surgical research; a platform for systematic data generation from well-designed, 
conducted, and reported trials; and provides a regulatory protective framework against 
potential harms of novel procedures before incorporation into practice10. 
 
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) is a 
transparent approach for assessing the CoE (also known as quality of evidence). GRADE 
approach is adopted and/or endorsed by more than 100 organizations including Cochrane and 
World Health Organization. The EAU Guidelines Office use modified GRADE for rating 
guidelines recommendations.  
According to GRADE, the outcomes included in a systematic review (SR) are scored on a scale 
of 1 to 9 [low importance to critically important for decision making]. Evidence from RCTs 
starts as “high” certainty, whereas evidence from non-randomised studies start as “low” 
certainty. There can be five reasons to possibly rate down the CoE:  i) methodological 
limitation of study design (risk of bias), ii) inconsistency, iii) indirectness, iv) imprecision and 
v) publication bias. There are 3 possible reasons to rate up the certainty of evidence (from non-
randomised studies): i) large magnitude of effect, ii) opposing plausible residual bias or 
confounding, iii) dose-response gradient. The guidelines recommendations are based upon 
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certainty of evidence of the critical outcomes, balance of benefits and harms, patients’ values, 
preferences and acceptability, and resource implication.  By considering the above factors a 
“strong” or “weak” recommendation, “for” or “against” an intervention can be made11. 
 
Safe and appropriate implementation of new treatments:  
 
Table 1 – Requirements for widespread implementation  
 
 Proof of concept study 
 Placebo/sham comparison study:  
 Randomised controlled trial against accepted alternative treatment  
 Cohort studies: to understand the generalisability and potential harms 
 Systematic reviews and meta-analysis of high-quality primary studies 
 How many patients should be included? – a sample size determination is needed 
 What should be the length of follow up?  
o Short- <12 months, medium- 12–36 months and long-term > 36 months.  
 Inclusion and exclusion criteria need to allow good generalisability  
 Relevant outcomes – varied and need to be clearly outlined from the start 
 
--------- 
 
To safely and effectively introduce novel techniques in the future there needs to be a 
systematic way of studying these new devices.  
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The studies should start with the publication of a proof of concept or ‘first in man’ trial 
followed by a randomised controlled trial against a sham (placebo) treatment. It is likely, 
although not essential, that these will come from experienced centres of excellence and need 
to follow established criteria including the usage of risk of bias assessment tools11,12,13. 
 
These studies should be followed by RCTs against TURP or a well-recognised and accepted 
MIT. The issue is what should be the comparator. For instance, an MIT like Rezum is 
perhaps a competitor between medical treatment and an ablative technique for BPO relief. 
Thus, has it to be as safe as a drug, or just safer than a more invasive ablative therapy, with a 
trade-off about reduced efficacy? 
 
Ideally two RCTs would be presented; one a non-inferiority trial on efficacy and one on 
safety, although these could come from a single study, if it is of a sufficiently high-quality 
design. It would be preferable to conduct multicentre studies with several surgeons, rather 
than single-centre or single-surgeon studies, to confirm the reproducibility of the principle. 
 
These should be followed by cohort studies; which will help with understanding the 
generalisability of the concept, allow secondary centres to gain experience and investigate for 
harms not necessarily shown in trials with selected study populations or short duration 
follow-up.  These should be mandatory to have the right to penetrate the market. 
 
Finally, come RCT-based SRs and/or meta-analyses; but this is on the proviso that there are 
sufficient high-quality RCTs in the first place. One reasonable question is, are systematic 
reviews currently done too soon before there are sufficient high quality RCTs? 
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The next question is; how many patients should be included? Clearly a sample size 
determination must be performed; this does not guarantee however, that the study will be 
powered for all the primary outcomes of interest. This calculation would be influenced by the 
expected difference between treatments and also by what we could call the ‘margin of 
inferiority’ that might be accepted for a less invasive treatment. Systematic reviewers are 
encouraged to calculate “optimal information size” (OIS). OIS is the minimum threshold of 
pooled estimate obtained from meta-analysis that is required for drawing reliable 
conclusions. 
 
What should be the length of follow up? This has been one of the greatest weaknesses in past 
trials. This is amplified in a systematic review of transurethral ablative procedures 
(techniques that have often been evaluated better than other MITs)14. They identified 69 
studies on LUT/BPO ablative surgical treatments over a 20-year period. The follow-up of 
these studies ranged from 1 to 100 months with a median follow up of just 12 months. 
Unsurprisingly, the longer the duration of follow-up, the fewer the number of trials available 
(Fig 1)  
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Fig 1 Follow-up of LUTS/BPO ablative studies. Adapted from Cornu JN et al. Reference 14. 
 
As noted by the authors “…further studies are needed to provide long-term comparative data 
and head-to head comparisons of emerging techniques.”  A reasonable suggestion therefore 
from the EAU non-neurogenic mLUTS Guideline Panel would be; i) short-term <12 months, 
ii) medium-term 12–36 months and iii) long-term > 36 months follow-up15. The outcome 
expectations of these studies may vary. If a therapy is very safe but with limited efficacy over 
time, but can be done again, it is more a trade-off with the patient. But these facts must be 
clear. This could be reflected in a guideline recommendation. 
 
Inclusion and exclusion criteria need to be broad enough to allow good generalisability of the 
technique. Sometimes the inclusion and exclusion criteria have been too stringent and make 
the studies not applicable to all the population. These must therefore, include factors such as 
variable prostate size and configuration and patients with or without retention after failed trial 
without catheter. Larger post-void residual volumes could be considered but may reflect more 
on poor detrusor function than BPO. Patients with a range of co-morbidities need to be 
included, certainly in the cohort studies, to note their potentials on treatment options with less 
morbidity for patients with more co-morbidities. This would include patients with a variety of 
anticoagulant needs. 
 
Before starting a clinical trial or a study, it is strongly recommended to check if there is an 
agreed minimum set of outcomes or outcome measures known as “core-outcomes set” 
(COS). The COS should be measured and reported by all new clinical trials and studies. 
“Core Outcome Measures in Effectiveness Trials” (COMET) 16 and the “International 
Consortium for Health Outcomes Measurement” (ICHOM) have developed COS for various 
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medical conditions. In a recent SR on the management of urinary retention in patients with 
LUTS/BPO, a broad search of the COMET database for a COS using the term “urology” in 
the disease category, yielded no directly applicable COS for the disease or treatments dealt 
with in that SR17. Outcomes important to all stakeholders; patients, the public, doctors and 
health-care decision makers need to be developed 18. COS should be checked first, and if they 
don’t exist, then the following outcomes should be considered for measurement and reporting 
(Table 2). Inconsistency in the measurement of outcomes, outcome-reporting bias, adds 
further to the problems faced by users of research who wish to make well-informed decisions 
about health care. 
 
 
Table 2. Potential Recordable Outcomes: -  
 
 Symptom assessment (e.g. IPSS, bladder diary) 
 Objective measurements (e.g. Flow rate, PVR and pressure flow studies) 
 Quality of life questionnaire(e.g.SF-36) 
 Patient satisfaction 
 Erectile and Ejaculatory function (e.g. IIEF and MSHQ-EjD) 
 Complications associated with the intervention 
 Length of stay and other hospital factors 
 Speed of return to normal activities 
 Need for additional medical treatment 
 Re-operation rates 
 Cost effectiveness (e.g. QALYs)  
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The appropriateness of some of these are obvious and will depend on the device being tested.  
With many of the new MITs the ability to preserve both erectile and ejaculatory function has 
been one of their potential positive benefits. Others such as the need for supplemental 
medical treatment will reflect both on the success of the treatment but may, in the case of 
overactive bladder symptoms, not be a sign of device failure. Overall however we have to 
recognise that concentrating on patient important-factors such as return to all normal 
activities can be more important to patients than a dramatic improvement in flow rate. The 
minimally important difference (MID) is the smallest change in a clinical outcome that 
patients perceive as important, either beneficial or harmful, which could result in the patient 
or doctor considering a change in treatment19. It has always represented a challenging 
concept in the management of LUTS.  It is generally accepted that patients will perceive a 
difference if their IPSS improves or deteriorates by 3 points or more, however, this varied 
considerably in the original paper and depended greatly on the baseline symptom score20. In 
addition, the MID is not an immutable characteristic, but may vary by population and 
context21.  The authors emphatically support the need for a clinical significance aspiration 
and not merely statistical significance. 
 
Currently in the literature, bipolar-TURP is the most investigated of the newer modalities 
with 56 RCTs and >6500 patients! But still CoE is not perfect for many of the investigated 
outcomes22,23 and it is much lower indeed for many of the other MIT procedures15. A simple 
PubMed search reveals 54 references for Urolift, 39 for Rezum, 248 for prostate artery 
embolisation (PAE) (because of many radiological technique papers), 42 for Aquablation and 
6 for iTIND devices. The very large majority of these papers, of course are not RCTs. 
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As a result of the quality of the information, devices and techniques will have varying 
recommendations in international guidelines over the years, such as those of the EAU (Table 
3) 
 
 
Table 3. Emerging technologies reviewed in the EAU LUTS guideline over three iterations of 
the guideline from 2009 to 2019 
 
Treatment EAU2009 EAU2015 EAU2019 
Bipolar TURP ND R R 
GreenLight ND R R 
PUL ND E R* 
Intraprostatic BTX ND E NR 
 
NR: Not Recommended R: Recommended    R*: Under conditions ND: Not Discussed E: Emerging 
 
Conclusions 
 
New modalities therefore need to achieve similar or better improvements in patient-important 
outcomes – as established treatments, such as bipolar TURP, or have lower risk of 
complications and side effects, or similar costs and shorter hospital stays. Evidence should 
include studies with long-term (> 3 years) follow-up. Preferably they should also improve 
urodynamic parameters such as maximum urinary flow rate and postvoid residual volumes24. 
There is clearly a difference however between the ideal treatment which might be cost-
effective, day-case, with few complications, good relief of BPO and good durability and the 
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ideal standard of evaluation which is all about safety and clinical effectiveness. These 
tradeoffs are clearly value- and preference sensitive and shared decision-making between 
patients and clinicians is therefore necessary.   
 
National organisations for example, the British, French, and German Urological 
Associations, and the international ones like the EAU should refuse to sanction new 
treatments (as they do when they devise patient information leaflets and procedure specific 
consent forms) until an agreed minimum threshold of CoE for the implementation of novel 
techniques for the surgical treatment of LUTS/BPO is available.  
However, we do not want an extended delay until effective treatments are fully implemented 
and therefore a national or better still a European initiative would allow new techniques to be 
used ONLY in research settings, such as structured cohort studies or registries, to collect 
crucial data about these early patients, and avoid or reduce the misuse under commercial 
pressure, particularly in private healthcare centres.  
 
This paper presents in a transparent way how the EAU Guideline Panel on non-Neurogenic 
mLUTS evaluates new invasive treatments and proposes the requirements and CoE that a 
new therapy should meet in order to be included in the Guidelines. It is our strong belief that 
the paper should trigger further discussions about the optimal way to assess new technology 
across all surgical disciplines, but that these devices should not be broadly implemented until 
at least quality RCTs on both safety and efficacy with adequate follow-up are completed. 
Contribution from patients’ organizations, device manufacturers and other stakeholders 
would be extremely important to formulate the optimal guidance. 
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